EMPOWER Trial
Phase 1/2
65
about 6.9 years
18–99
3 sites in CA, FL
What this study is about
This trial is testing a new treatment called Sarilumab plus Capecitabine in people with triple-negative breast cancer. The goal is to see if it can help eliminate minimal residual disease (MRD) after standard treatments, potentially improving survival and cure rates for this aggressive type of breast cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Capecitabine
- 2.Take Sarilumab 150mg or 200 mg plus Capecitabine
- 3.Take Sarilumab 150mg plus Capecitabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine, sarilumab, ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Tablet)
Primary: Phase I: Dose-limiting toxicity (DLT), Phase I: Maximum Tolerated Dose (MTD)
Oncology